Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Access Outlicenses China Rights for Mucositis Product to RHEI

publication date: Jan 14, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Access Pharmaceuticals has licensed the China marketing rights for its oral mucositis product, MuGard™, to RHEI Pharma, a US-based company that specializes in bringing proprietary medications to China. RHEI says it has 110 national sales reps with access to large volume hospitals in China. But first, RHEI must put the product through the SFDA approval process. Once approved, RHEI will manufacture the product in China and seek to market it throughout Southeast Asia. More details...

Stock Symbol: (OTCBB: ACCP)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...